Navigation Links
ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report
Date:2/2/2010

DALLAS, Texas, February 2 /PRNewswire/ -- ReportsandReports announce to have Biosimilars Series: Forecast Analysis (http://www.reportsandreports.com/market-reports/biosimilars-series-Forecast- Analysis/) Market Research Report in its store

The high cost and utilization of biologic drugs, coupled to the growing need to curb pharmaceutical expenditure, provides considerable momentum to the emerging biosimilars market. With a biosimilar approval pathway in place in Europe and Japan, and imminently in the US, Datamonitor expects payer pressure to drive biosimilar uptake, particularly in Germany, the US, and the UK.

    Scope

    - Molecule-specific forecasts for biosimilar epoetin alpha, filgrastim,
      interferon beta, interferon alpha, human growth hormone, and
      insulin-glargine.

    - Molecule-specific forecasts for France, Germany, Italy, Spain, the US,
      and Japan through 2019.

    - An overview of the emerging biosimilars market, including a regulatory
      update.

    - An outline of the key issues which will impact on biosimilars uptake
      going forward.

Highlights

As the first to introduce guidelines for biosimilar drug approval, Europe has emerged as the testing ground for biosimilar drugs, with biosimilars for three biologics having entered the market to date human growth hormone, epoetin alpha, and filgrastim.

The size of the US market, combined with the voracious generic erosion that characterize it, make it an attractive prospect for would-be biosimilars makers, and as such, it represents the real prize, contingent on the creation of a biosimilars approval pathway.

Although guidance for biosimilar approval was issued in Japan in 2009, this market is unlikely to experience significant biosimilar incursion through the forecast period, contributing at most 1% to total seven major market volume sales in 2019.

    Reasons to Purchase

    - Learn how biosimilar uptake for six biologic drugs is anticipated to
      change through 2019, in France, Germany, Italy, Spain, the UK, the US,
      and Japan.

    - Understand how the seven major markets compare in terms of speed and
      extent of biosimilars uptake.

    - Identify the key molecule and market specific drivers and resistors to
      biosimilar uptake.

Related Reports

HVAC in the U.S., 2nd Edition - Green and Global ( http://www.reportsandreports.com/market-reports/hvac-in-the-us-2nd-edition-%E 2%80%94-green-and-global/)

Global Biomaterial Market (2009-2014) ( http://www.reportsandreports.com/market-reports/global-biomaterial-market-200 9-2014/)

World Market for Biosimilars and the Potential for US Followon Biologics (http://www.reportsandreports.com/market-reports/world-market-for-biosimilars -and-the-potential-for-us-followon-bi/)

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)

    Contact:

    Ms. Sunita
    7557 Rambler road,
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004
    http://www.reportsandreports.com/


SOURCE MarketsandMarkets


'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. BioVascular Inc. Closes $10.87 Million Series C Financing
3. PG500 Series Presented at the AACR Annual Meeting in San Diego
4. Light Sciences Oncology Raises $40.1 Million in Series C Financing
5. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
6. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
7. Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments
8. Lutonix Inc. Announces $20 Million Series B Financing
9. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):